News & Events

Learn about what's new with CMC Biologics

AGC Biologics Expands Plasmid DNA Offering

News

SEATTLE, December 11, 2019-- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany. With the demand for pDNA growing rapidly, AGC Biologics is leveraging 25 years of experience and comprehensive in-house analytics development to ensure customers short and dependable timelines.

AGC Biologics’ $18m Investment in Seattle and Denmark Facilities Strengthens Global Footprint

News

SEATTLE, WA -- November 11th, 2019 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded, as part of an ongoing commitment to deliver the highest standard of service for their customers.

AGC Biologics Appoints New Site Head/General Manager  of Copenhagen, Denmark Operations

News

Jeffrey D. Mowery Named Site Head/General Manager

AGC Biologics Appoints New Site Head/General Manager  of Chiba, Japan Operations

News

Naofumi Kagami Named Site Head/General Manager

AGC Biologics Appoints New Chief Technical Officer

News

Kasper Møller named Chief Technical Officer

AGC Biologics Appoints New Site Head/General Manager of Bothell, WA Operations

News

BOTHELL, WA. -- May 15, 2019 -- AGC Biologics, a global leader in clinical and commercial manufacturing

U.S. Congresswoman, Suzan DelBene, Visits AGC Biologics Corporate Headquarters

News

On Thursday, April 25th, AGC Biologics welcomed U.S. Congresswoman, representing Washington’s 1st District, Suzan DelBene to our global headquarters in Seattle, WA. The purpose of Congresswoman DelBene’s visit was to highlight our high school internship program, Project BioPath, a first of its kind offering designed to give high school students hands-on training, real-world work experience and a pathway to job opportunities at AGC Biologics and other biotechnology companies. We are proud and excited about the success and visibility this project is gaining and Congresswoman DelBene’s visit was an inspiration for us to continue investing in the talent of tomorrow.

Dr. Gustavo Mahler Resigns as Chief Executive Officer of AGC Biologics, Patricio Massera to Succeed as CEO Effective May 1st, 2019

News

BOTHELL, Washington, April 2, 2019 /PRNewswire/ -- 

AGC Biologics today announces a change in executive leadership. Dr. Gustavo Mahler has decided to leave his position as CEO effective April 30th, 2019 after a 10 year tenure with CMC Biologics and AGC Biologics. Dr. Mahler will continue on as a member of the Board of Directors . Patricio Massera, previously the Chief Operating Officer for AGC Biologics, will succeed Dr. Mahler as the Chief Executive Officer, effective May 1st 2019.

Gustavo joined AGC Biologics (previously CMC Biologics) in 2008 as President. In 2010, he was named global Chief Operations Officer and in January, 2016 he became Chief Executive Officer. "The transition of Patricio to the CEO role is carefully planned," stated Gustavo.  "It has been a sincere pleasure to lead AGC Biologics and I am proud of all we accomplished. I am thankful for the opportunity to have worked with a world-class team of professionals and advance the pipeline of our customers to market."

Washington State Governor Jay Inslee Visits AGC Biologics Corporate Headquarters

News

On Friday, March 22nd, AGC Biologics welcomed Washington State Governor Jay Inslee to its global headquarters in Bothell, WA. Along with the Governor, we also welcomed representatives from Edmonds School District, our educational partner. The purpose of the Governor’s visit was to highlight our new paid high school internship program, Project BioPath, to train students from our region to fill jobs we have to offer. The new internship program is designed to give high school students hands-on training, real-world work experience and a pathway to job opportunities at AGC Biologics and other biotechnology companies. With the launch of Project BioPath, we are pursuing a strategy to increase the available talent pool for our company and the greater industry.

AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002

News

AGC-Biologics-SMALLER-LOGO-1COPENHAGEN, Denmark and AMSTERDAM, Feb. 19, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and Calypso Biotech B.V. (Calypso), a biotechnology company focused on the development of novel therapeutic antibodies in the inflammation/autoimmune therapeutic areas announced today that they have entered into an agreement for the process development and cGMP manufacture of CALY-002, a humanized monoclonal antibody inhibiting Interleukin-15 (IL-15). Under the agreement, AGC Biologics will develop and scale up a process for cGMP manufacture of CALY-002 in its world class facility in Copenhagen, Denmark to support Calypso's clinical trials in Europe.

IL-15 is an immune checkpoint cytokine that controls inflammation as well as the fate of multiple immune cells. Especially, IL-15 was recently recognized as a key factor in the survival of tissue-resident memory T cells, a population of immune cells involved in disease maintenance and recurrence. Calypso scientists believe that targeting tissue-resident memory T cells with CALY-002 offers significant advantages and potential in multiple autoimmune indications, including unprecedented disease-modifying effects.

"We are pleased to be working with Calypso on this exciting and innovative monoclonal antibody product," said Gustavo Mahler, PhD, Chief Executive Officer of AGC Biologics "With our extensive experience developing and manufacturing monoclonal antibody products, we are well positioned to help Calypso deliver this innovative antibody treatment to patients."

"We selected CMC Biologics as our manufacturing partner because of their ability to support our accelerated program for CALY-002, since they have extensive experience working with monoclonal antibodies combined with their very broad development and manufacturing capabilities," said Alain Vicari, DVM, PhD, Chief Executive Officer of Calypso. "The successful process development and manufacture of CALY-002 is critical to Calypso meeting our aggressive clinical development timelines."

About Calypso Biotech

Calypso Biotech is an immunotherapy biotech company, spin-off from Merck Serono, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. Calypso Biotech is headquartered in Amsterdam, the Netherlands, with offices and laboratories in Geneva, Switzerland, and is also a resident company of Johnson & Johnson Innovation -JLABS (JLABS @ BE) in Beerse, Belgium, a premier life science incubator program. For more information on Calypso Biotech, please see https://www.calypsobiotech.com

About AGC Biologics

AGC Biologics is a leading global Contract Development and Manufacturing Organization, with a strong commitment to deliver the highest standard of service to our clients. AGC Biologics has an extensive network of cGMP facilities in the US, Europe and Asia. We offer deep industry expertise, innovative solutions and technologies, and customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial, for mammalian and microbial. We forge exceptionally strong partnerships with our clients, and we never lose sight of our pledge to deliver reliable and compliant drug substance supply, on time. For more information, visit www.agcbio.com.

Calypso Biotech Media Contact Information:
Alain VICARI DVM, PhD
Chief Executive Officer
Calypso Biotech BV
Email: info@calypsobiotech.com

AGC Biologics Media Contact Information:
Diane Hunt
Head of Global Marketing
Email: dhunt@agcbio.com

Follow Us
Join us on LinkedIn Follow us on Twitter